About Dual specificity protein phosphatase 5
Dual specificity protein phosphatase 5 (DUSP5) is a protein
from Homo sapiens identified by UniProt accession
Q16690, 384 residues long.
MolForge cross-references it against 0 known binders and
222 disease associations.
Target properties
| Protein name | Dual specificity protein phosphatase 5 |
|---|
| UniProt accession | Q16690 |
|---|
| Gene | DUSP5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 384 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (222)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.37
- Crohn's disease · score 0.36
- thyroid gland adenocarcinoma · score 0.30
- glioblastoma multiforme · score 0.30
- inflammatory bowel disease · score 0.26
- serum non-albumin protein measurement · score 0.25
- bone density · score 0.24
- cutaneous melanoma · score 0.18
- endometrial cancer · score 0.18
- melanoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q16690-F1 | alphafold | PREDICTED | 77.62 | — |
Amino-acid sequence (384 residues)
MKVTSLDGRQ LRKMLRKEAA ARCVVLDCRP YLAFAASNVR GSLNVNLNSV VLRRARGGAV SARYVLPDEA ARARLLQEGG GGVAAVVVLD QGSRHWQKLR EESAARVVLT SLLACLPAGP RVYFLKGGYE TFYSEYPECC VDVKPISQEK IESERALISQ CGKPVVNVSY RPAYDQGGPV EILPFLYLGS AYHASKCEFL ANLHITALLN VSRRTSEACA THLHYKWIPV EDSHTADISS HFQEAIDFID CVREKGGKVL VHCEAGISRS PTICMAYLMK TKQFRLKEAF DYIKQRRSMV SPNFGFMGQL LQYESEILPS TPNPQPPSCQ GEAAGSSLIG HLQTLSPDMQ GAYCTFPASV LAPVPTHSTV SELSRSPVAT ATSC
Explore Dual specificity protein phosphatase 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets